 |
인쇄하기
취소
|
Green Cross’s Hunterase gets orphan drug designation from US FDA
Green Cross Corp. said Monday its new drug Hunterase has been recently designated as orphan drug by the U.S. Food and Drug Administration.
The company plans to file the New Drug Application (NDA) for Hunterase within this year.
Under the U.S. law, companies that develop such a drug (a drug for a disorder affecting fewer than 200,000 people) may sell it without competition for seven years,...
The company plans to file the New Drug Application (NDA) for Hunterase within this year.
Under the U.S. law, companies that develop such a drug (a drug for a disorder affecting fewer than 200,000 people) may sell it without competition for seven years,...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.